Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference
11 oct. 2018 08h00 HE
|
Celtaxsys, Inc.
ATLANTA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Full results from the recently completed Phase 2 trial (EMPIRE-CF) of Celtaxsys’ acebilustat will be presented at the North American Cystic Fibrosis...
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
02 août 2018 08h00 HE
|
Celtaxsys, Inc.
-Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients --Celtaxsys,...
Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July
17 mai 2018 08h00 HE
|
Celtaxsys, Inc.
ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage
13 févr. 2018 08h00 HE
|
Arch Biopartners
TORONTO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) a portfolio based biotechnology company, announced today the investigator...
Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
04 janv. 2018 08h00 HE
|
Celtaxsys, Inc.
ATLANTA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the...
Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines
16 mai 2016 07h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced a three-year agreement with Cystic Fibrosis Foundation...
Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients
01 oct. 2015 08h03 HE
|
Celtaxsys Inc.
ATLANTA, GA--(Marketwired - October 01, 2015) - Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today...